AMRX Amneal Pharmaceuticals
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2021
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
(Former Name or Former Address, if Changed Since Last Report)
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Class A Common Stock, par value $0.01 per share||AMRX||New York Stock Exchange|
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On April 5, 2021, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Amneal Pharmaceuticals LLC, a subsidiary of the Company, completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this report furnished pursuant to Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
Item 9.01 Exhibits.
See the Exhibit Index below, which is incorporated by reference herein.
|99.1||Press release dated April 5, 2021 (furnished pursuant to Item 7.01).|
|104||The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.|
|Date: April 5, 2021||AMNEAL PHARMACEUTICALS, INC.|
/s/ Anastasios Konidaris
|Title:||Executive Vice President and Chief Financial Officer|